You are here

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Last updated on October 12, 2018

FOR MORE INFORMATION
Study Location
Clinical Research Advantage, Inc./Fountain Hills Family Practice, P.C.
Fountain Hills, Arizona, 85268 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
60-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Evidence of a personally signed and dated informed consent document (ICD) indicating
that the subject has been informed of all pertinent aspects of the study.

2. Healthy adults who are determined by medical history, physical examination, and
clinical judgment of the investigator to be eligible for inclusion in the study.

3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests,
and other study procedures.

4. Sentinel-cohort subjects only: Male and nonchildbearing-potential female adults aged
60 to 85 years at the time of enrollment (signing of the ICD).

5. Expanded-cohort subjects only: Male and nonchildbearing-potential female adults aged
65 to 85 years at the time of enrollment (signing of the ICD).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Sentinel-cohort subjects only: Any screening hematology and/or blood chemistry
laboratory value that meets the definition of a ? Grade 1 abnormality.

2. Sentinel-cohort subjects only: Positive test for human immunodeficiency virus
(HIV),hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or
hepatitis C virus antibodies (HCV Abs) at the screening visit.

3. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.

4. Participation in other studies involving investigational product within 28 days prior
to study entry and/or during study participation.

5. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).

6. Previous vaccination with any licensed or investigational RSV vaccine, or planned
receipt throughout the study of nonstudy RSV vaccine.

7. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the investigational product(s), or
history of severe allergic reaction (eg, anaphylaxis) to any substance.

8. Immunocompromised subjects with known or suspected immunodeficiency, as determined by
history and/or laboratory/physical examination.

9. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
planned receipt throughout the study. If systemic corticosteroids have been
administered short term ( not be enrolled into the study until corticosteroid therapy has been discontinued for
at least 28 days before investigational product administration. Intra-articular,
intrabursal, or topical (epidural, skin or eyes) corticosteroids are permitted.

10. Subject with a history of autoimmune disease or an active autoimmune disease requiring
therapeutic intervention including but not limited to: systemic or cutaneous lupus
erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré
syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura,
glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis),
psoriasis, and insulin-dependent diabetes mellitus (type 1).

11. Receipt of blood/plasma products or immunoglobulin, from 60 days before
investigational product administration or planned receipt throughout the study.

12. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.

13. Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.

14. Female subjects of childbearing potential; pregnant female subjects; breastfeeding
female subjects; fertile male subjects who are unwilling to use a highly effective
method of contraception for at least 28 days after the last dose of investigational
product.

15. Expanded-cohort subjects only: Vaccination with any influenza vaccine within 6 months
(182 days) before investigational product administration.

16. Expanded-cohort subjects only: Allergy to egg proteins (egg or egg products) or
chicken proteins.

NCT03572062
Pfizer
Suspended
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Respiratory Tract Infection
NCT03572062
All Genders
60+
Years
Multiple Sites
Clostridium Difficile Infection
NCT03090191
All Genders
50+
Years
Multiple Sites
Cryptococcal Meningitis, HIV Infections
NCT00002068
All Genders
13+
Years
Multiple Sites
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study to Describe the Safety, Tolerability, and Immunogenicity of an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Healthy Older Adults
The study will evaluate the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations, some with adjuvant, when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
The study will evaluate the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations, some with adjuvant, when administered alone or concomitantly with SIIV. Healthy male and female subjects between 60 to 85 years of age will be enrolled. Subjects in the sentinel cohort will receive one of two RSV vaccine formulations at one of 3 antigen dose levels or placebo. Subjects in the expanded cohort will receive one of two RSV vaccine formulations at one of 3 antigen dose levels with or without SIIV.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Parallel

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Observer blind

Primary Purpose: Prevention

Respiratory Tract Infection
  • Biological: Formulation A
    RSV vaccine
  • Biological: Formulation B
    Adjuvanted RSV vaccine
  • Biological: Placebo
    Placebo
  • Experimental: Sentinel Arm 1
    Low dose formulation A
    Intervention: Biological: Formulation A
  • Experimental: Sentinel Arm 2
    Low dose formulation B
    Intervention: Biological: Formulation B
  • Experimental: Sentinel Arm 3
    Mid dose formulation A
    Intervention: Biological: Formulation A
  • Experimental: Sentinel Arm 4
    Mid dose formulation B
    Intervention: Biological: Formulation B
  • Experimental: Sentinel Arm 5
    High dose formulation A
    Intervention: Biological: Formulation A
  • Experimental: Sentinel Arm 6
    High dose formulation B
    Intervention: Biological: Formulation B
  • Placebo Comparator: Sentinel Arm 7
    Placebo
    Intervention: Biological: Placebo
  • Experimental: Expanded Arm 8
    Low dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Expanded Arm 9
    Low dose formulation B and placebo
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 10
    Low dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 11
    Mid dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Expanded Arm 12
    Mid dose formulation B and placebo
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 13
    Mid dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 14
    High dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Expanded Arm 15
    High dose formulation B and placebo
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 16
    High dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Expanded Arm 17
    Placebo and Placebo
    Intervention: Biological: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
474
Same as current
October 30, 2019
October 30, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
  2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.
  4. Sentinel-cohort subjects only: Male and nonchildbearing-potential female adults aged 60 to 85 years at the time of enrollment (signing of the ICD).
  5. Expanded-cohort subjects only: Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of enrollment (signing of the ICD).

Exclusion Criteria:

  1. Sentinel-cohort subjects only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ? Grade 1 abnormality.
  2. Sentinel-cohort subjects only: Positive test for human immunodeficiency virus (HIV),hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit.
  3. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  4. Participation in other studies involving investigational product within 28 days prior to study entry and/or during study participation.
  5. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
  6. Previous vaccination with any licensed or investigational RSV vaccine, or planned receipt throughout the study of nonstudy RSV vaccine.
  7. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product(s).
  8. Immunocompromised subjects with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  9. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  10. Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  11. Receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration or planned receipt throughout the study.
  12. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  13. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  14. Female subjects of childbearing potential; pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling to use a highly effective method of contraception for at least 28 days after the last dose of investigational product.
  15. Expanded-cohort subjects only: Vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration.
  16. Expanded-cohort subjects only: Allergy to egg proteins (egg or egg products) or chicken proteins.
Sexes Eligible for Study: All
60 Years to 85 Years   (Adult, Older Adult)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT03572062
C3671002
RSV ADJUVANT ( Other Identifier: Alias Study Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now